Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood BR, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Harrison J, Hölscher C, Brooks DJ, Passmore AP, Ballard C, Edison P. Femminella GD, et al. Among authors: harrison j. Trials. 2019 Apr 3;20(1):191. doi: 10.1186/s13063-019-3259-x. Trials. 2019. PMID: 30944040 Free PMC article. Clinical Trial.
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group. Lannfelt L, et al. Among authors: harrison j. Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Lancet Neurol. 2008. PMID: 18672400 Clinical Trial.
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI. Faux NG, et al. Among authors: harrison j. J Alzheimers Dis. 2010;20(2):509-16. doi: 10.3233/JAD-2010-1390. J Alzheimers Dis. 2010. PMID: 20164561 Clinical Trial.
A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility.
Jutten RJ, Harrison J, Lee Meeuw Kjoe PR, Opmeer EM, Schoonenboom NSM, de Jong FJ, Ritchie CW, Scheltens P, Sikkes SAM. Jutten RJ, et al. Among authors: harrison j. Alzheimers Dement (Amst). 2017 Dec 27;10:153-160. doi: 10.1016/j.dadm.2017.12.002. eCollection 2018. Alzheimers Dement (Amst). 2017. PMID: 29780863 Free PMC article.
Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort.
Jutten RJ, Harrison JE, Lee Meeuw Kjoe PR, Ingala S, Vreeswijk R, van Deelen RAJ, de Jong FJ, Opmeer EM, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM. Jutten RJ, et al. Among authors: harrison je. Alzheimers Res Ther. 2019 May 15;11(1):45. doi: 10.1186/s13195-019-0500-5. Alzheimers Res Ther. 2019. PMID: 31092277 Free PMC article.
4,245 results